CYCC

Cyclacel Pharmaceuticals, Inc.

2.55 USD
-0.01 (-0.39%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Cyclacel Pharmaceuticals, Inc. stock is up 13.84% since 30 days ago. The next earnings date is Mar 12, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 44.44% of the previous 18 March’s closed higher than February.

About Cyclacel Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals, Inc. develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) and CYC140. Sapacitabine, a nucleoside analog that is orally available prodrug of CNDAC, is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome.